Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer

被引：0
|
作者：
Edurne Arriola
Socorro Maria Rodriguez-Pinilla
Maryou B. K. Lambros
Robin L. Jones
Michelle James
Kay Savage
Ian E. Smith
Mitch Dowsett
Jorge S. Reis-Filho
机构：
[1] Institute of Cancer Research,The Breakthrough Breast Cancer Research Centre
[2] Royal Marsden Hospital,Department of Academic Biochemistry
[3] Royal Marsden Hospital,Breast Unit
来源：
Breast Cancer Research and Treatment | 2007年 / 106卷
关键词：
Anthracyclines; Breast cancer; Chromogenic ; hubridisation; HER2; Topoisomerase II alpha;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：181 / 189
页数：8
相关论文
共 50 条
  • [1] Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
    Arriola, Edurne
    Rodriguez-Pinilla, Socorro Maria
    Lambros, Maryou B. K.
    Jones, Robin L.
    James, Michelle
    Savage, Kay
    Smith, Ian E.
    Dowsett, Mitch
    Reis-Filho, Jorge S.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (02) : 181 - 189
  • [2] HER2 status and benefit from adjuvant trastuzumab in breast cancer
    Paik, Soonmyung
    Kim, Chungyeul
    Wolmark, Norman
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (13): : 1409 - 1411
  • [3] Topoisomerase II-Alpha and HER2 gene co-amplification as a predictorof response to therapy and survival in HER2 positive metastatic breast carcinoma
    Kapoor, A.
    Brufsky, A.
    Chow, S.
    Rosenzweig, M.
    Surti, U.
    Bhargava, R.
    MODERN PATHOLOGY, 2007, 20 : 38A - 38A
  • [4] Topoisomerase II-Alpha and HER2 gene co-amplification as a predictor of response to therapy and survival in HER2 positive metastatic breast carcinoma
    Kapoor, A.
    Brufsky, A.
    Chow, S.
    Rosenzweig, M.
    Surti, U.
    Bhargava, R.
    LABORATORY INVESTIGATION, 2007, 87 : 38A - 38A
  • [5] Final results of a meta-analysis testing HER2 and topoisomerase IIα genes as predictors of incremental benefit from anthracyclines in breast cancer.
    Di Leo, A.
    Desmedt, C.
    Bartlett, J. A.
    Ejlertsen, B.
    Pritchard, K. I.
    Poole, C. J.
    Larsimont, D.
    Tanner, M.
    Plette, F.
    Buyse, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Amplification of Topoisomerase 2 Alpha (TOP2A) in HER2/neu Negative Breast Cancer
    Glynn, R. W.
    Mahon, S.
    Miller, N.
    Callagy, G.
    Kerin, M. J.
    CANCER RESEARCH, 2010, 70
  • [7] Adjuvant therapy in breast cancer HER2 positive
    Olivito, V.
    De Simone, R.
    La Gattuta, G.
    Lucia, M.
    Dima, G.
    Talarico, R.
    Filippelli, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII146 - VII146
  • [8] Application of neo-bioscore staging to predict the benefit of pertuzumab in HER2 positive early breast cancer
    Sanchez Escudero, L.
    Morales Pancorbo, D.
    Bayo, J.
    Aragon Manrique, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S442 - S443
  • [9] HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
    Gennari, Alessandra
    Sormani, Maria Pia
    Pronzato, Paolo
    Puntoni, Matteo
    Colozza, Mariantonietta
    Pfeffer, Ulrich
    Bruzzi, Paolo
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01): : 14 - 20
  • [10] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    J. Lluch-Gómez
    V. Núñez-Álvarez
    C. de la Torre-Hita
    M. Bernal-Gómez
    A. Campini-Bermejo
    E. Perdomo-Zaldívar
    L. Rodríguez-Pérez
    J. Calvete-Candenas
    M. J. Martínez-Bautista
    E. Benítez-Rodríguez
    J. M. Baena-Cañada
    Scientific Reports, 13
12345